Compare JBS N.V. Class A Common Shares (JBS) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JBS N.V. Class A Common Shares vs Eli Lilly And Co — how do they compare? JBS N.V. Class A Common Shares trades at $13 (market cap $13.86B), while Eli Lilly And Co trades at $1,221.14 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 75× JBS N.V. Class A Common Shares's market cap, and JBS N.V. Class A Common Shares pays the higher dividend (10.38%). Which is the better fit depends on your goals — on Pluang, investors hold JBS N.V. Class A Common Shares for 0 Days and Eli Lilly And Co for 94 Days on average.
| JBS | LLY | |
|---|---|---|
Market Cap | $13.86B | $1.04T |
Volume | 4,980,049 | 1,843,375 |
Sector | Consumer Staples | Health |
52-Week High | $18.42 | $1.28K |
52-Week Low | $10.86 | $799.57 |
Typical Hold Time | 0 Days | 94 Days |
Enterprise Value | $34.83B | $1.09T |
Dividend Yield | 10.38% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBS trades at $12.93, up 0.54% today, with a neutral technical signal and strong analyst buy consensus. The stock shows attractive valuation with a P/E of 12.08 and P/S of 0.47, though recent quarterly EPS misses and a declining profit margin to 1.22% in 2026 highlight earnings pressure. Recent news includes a proposal to acquire full control of Pilgrim's Pride and a joint venture in Southeast Asia, indicating strategic expansion.
The outlook is mixed: analyst targets suggest ~40% upside to $18.17, but risks include execution on acquisitions, margin compression, and volatile beef markets. Cash flow turned positive in 2026 projections, supporting growth initiatives, yet debt levels and competitive pressures warrant caution for investors seeking stability.
Eli Lilly (LLY) trades at $1,211.40, up 2.43% today, with a bullish technical outlook and strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 surpassing the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights pipeline advancements in weight-loss drugs, including EloraTZP's promising trial results.
Outlook remains positive given dominant market position in obesity and diabetes treatments, with analyst consensus price target of $1,350 implying ~11% upside. Key risks include competitive pressures from Novo Nordisk and regulatory hurdles. Earnings growth and pipeline catalysts support further appreciation, though high valuations warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JBS N.V. Class A Common Shares
JBS N.V. is a protein-processing company producing beef, pork, poultry, lamb, fish, and plant-based products, headquartered in São Paulo and Amsterdam. It operates more than 250 production facilities across over 16 countries under brands including Friboi, Seara, Swift, and Pilgrim's, and is the majority shareholder of Pilgrim's Pride Corporation.
Read more on JBS →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
